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KEBERKESANAN DAN DAYA KETAHANAN TERHADAP PENGGUNAAN 
PREGABALIN DALAM KALANGAN PESAKIT DI HOSPITAL RAJA FAHAD, ARAB 
SAUDI: SATU KAJIAN QUASI -LONGITUDINAL 
ABSTRAK 
 
Satu kajian membujur kuasi eksperimen bukan rawak telah dijalankan untuk menilai 
keberkesanan serta keselamatan dan ketoleranan pengambilan 75mg pregabalin pos hemodialisis 
(pHD) sekali sehari secara lisan, bagi uremic pruritus (UP) yang resistan pada rawatan, di 
kalangan pesakit ESRD dalam pusat buah pinggang Aljaber, Hospital King Fahad, Alahsa Arab 
Saudi. Pengukuran untuk keterukan dan intensiti gatal dilakukan dengan menggunakan skala 
gatal-5D versi Bahasa Arab yang telah divalidasi (α = 0.847 p = 0.001, Kaiser- Meyer-Oklin 
value = 0.810). Pengukuran tahap selamat dan ketoleranan pada pregabalin telah dilakukan 
dengan menggunakan algoritma Naranjo. Model linear teritlak digunakan untuk mengukur kesan 
selang waktu pengambilan pregabalin. Selanjutnya, untuk menentukan perbezaan kesan 
pregabalin pada selang masa yang berbeza, persamaan anggaran teritlak digunakan. Akhirnya 
untuk pentaksiran hubungan unsur-unsur demografi dan tahap keterukan UP, simulasi Monte 
Carlo telah dipilih. Dalam jangka masa kajian, seramai pesakit hemodialisis (N=96) didapati 
layak dimasukkan dalam kajian. Walau bagaimanapun, apabila dikenakan kriteria kemasukan 
dan pengecualian, hanya 51 orang pesakit telah dipertimbangkan untuk terapi pregabalin. 
Penilaian keterukan dan intensiti UP dilaksanakan empat kali; iaitu penilaian garis asas (hari 0), 
penilaian awal (hari ke-14), penilaian hasil primer (28 hari), dan penilaian hasil sekunder (hari 
42). Pada penilaian garis asas skor median 5D-IS adalah 19, yang menurun kepada 8 pada hari ke 
28 dan kepada 6 pada hari ke 42. Berbanding dengan garis asas 5D-IS terdapat pengurangan 12 
mata untuk setiap pesakit pada hari ke 42 [B = - 12,729 (CI -13,257 -  -12,201)]. Mengambilkira 
pengurangan 12.729 dalam skor, ternyata bahawa pesakit yang mengalami gatal-gatal yang teruk 
xviii 
 
mendapat kelegaan ketara selepas menggunakan pregabalin 75 mg (pHD) selama 42 hari (p = 
<0.001). Antara faktor-faktor demografi, jantina didapati mempunyai hubungan yang signifikan 
5D-IS Rata (B = 0,102, CI -0,498 - 0,720, p = 0.032). Secara keseluruhan, terdapat peningkatan 
yang ketara dalam kualiti tidur selepas menggunakan pregabalin selama 42hari (B = -2,500, p = 
<0.001 *). Tahap kalsium serum tinggi didapati mempunyai gangguan tidur tinggi berbanding 
dengan mereka yang normal (B = 1.302, p = 0.002 *). Di samping itu peningkatan dalam kualiti 
tidur di kalangan pesakit lelaki adalah lebih tinggi berbanding pesakit wanita (B = -0,216). 
Pentaksiran keselamatan pregabalin mendedahkan bahawa mengantuk dan pening merupakan 
dua kesan advers (Adverse Events - AEs) yang kerap; diikuti dengan sembelit (29.4%), 
pertambahan berat badan (11.8%) dan edema (9.8%). Kuantifikasi Naranjo bagi kemungkinan 
dan kebarangkalian AEs mencerminkan bahawa semua jangkaan yang berlaku adalah 
berkemungkinan.  Asosiasi ketara dicerap dalam kalangan umur - pertambahan berat badan 
(0.040 *), sejarah penyakit - penglihatan kabur (0.046 ) dan sejarah penyakit - edema (0,049). 
Bersama-sama dengan penemuan AEs ini, 75 mg pregabalin (pHD) didapati pilihan rawatan 
yang berkesan untuk pengurusan rawatan UP yang resistan pada rawatan dan telah diterima baik 
oleh semua pesakit. 
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EFFECTIVENESS AND TOLERABILITY OF PREGABALIN USAGE AMONG 
PATIENTS IN KING FAHAD HOSPITAL, SAUDI ARABIA: A QUASI 
LONGITUDINAL STUDY 
ABSTRACT 
A quasi, non-randomized longitudinal study was conducted to assess the effectiveness of 75mg 
pregabalin post hemodialysis (pHD) once daily orally in treatment-resistant uremic pruritus 
(UP), and the safety and tolerability among ESRD patients at Aljaber kidney center, King Fahad 
Hospital, Alahsa Saudi Arabia. Assessment for the severity and intensity of itching was done 
using the validated Arabic version of 5D- itching scale (α= 0.847, p=0.001, Kaiser- Meyer-Oklin 
value= 0.810). Safety and tolerability of pregabalin was done by using Naranjo’s algorithm. The 
effect of the pregabalin over the time was assessed using the generalized linear model. 
Furthermore, to pinpoint the differences in the effect of pregabalin at different time intervals, 
generalized estimated equations were used. Finally for the assessment of the association among 
demographics and UP severity, Monte Carlo simulations were preferred. During the time frame 
of study about 96 hemodialysis patients were found eligible to be enrolled in the study. However, 
upon apply the inclusion and exclusion criteria, only 51patients were considered for pregabalin 
therapy. Assessment of severity and intensity of UP was done at four occasion i.e. baseline 
assessment (day 0), initial assessment (day 14), assessment of primary outcome (day 28), and 
assessment of secondary outcome (day 42). At the base line assessment the 5D-IS median score 
was 19, which reduced to 8 at the day 28 and to 6 on day 42.  In comparison to the baseline 5D-
IS there was a reduction of 12 points for each patients on day forty two [B= - 12.729 (CI -13.257 
– -12.201)].  Keeping in view the reduction of 12.729 in the score revealed that the patient who 
was suffering from a severe itching got a major relief after using pregabalin 75 mg (PHD) for 
day 42 (p = <0.001). Among all demographic factors gender was found significantly associated 
xx 
 
5D-IS score (B= 0.102, CI -0.498 – 0.720, p= 0.032). Overall, there was a significant 
improvement in the sleep quality after using pregabalin for 42 days (B= -2.500, p=<0.001). High 
serum calcium level were found to have high sleep disturbances in comparison to those who are 
normal (B= 1.302, p= 0.002).  In addition improvement in sleep quality among male patients was 
higher than the female patients (B=-0.216). Assessment of safety of pregabalin revealed that 
somnolence and dizziness were the two frequents adverse events (AEs) followed by constipation 
(29.4%), weight gain (11.8%) and edema (9.8%). Naranjo’s quantification for the possibility and 
probability of AEs reflect that all the events were probable. Significant association were 
observed among age – weight gain (0.040), disease history in years – blurred vision (0.046) and 
disease history in years – edema (0.049). Along with these AEs 75 mg pregabalin (pHD) was 
found and effective treatment option for the management of treatment resistant UP and was well 
tolerated by all patients.  
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CHAPTER ONE 
INTRODUCTION 
1.0 Background   
 
According to the  Kidney Disease Outcome Quality Initiative (KDOQI), Chronic Kidney 
Disease (CKD) refers to an immediate or gradual decrease in renal function or efficiency for a 
duration of more than three months (KDOQI., 2002). The criteria to assess the disease initiation 
are urinary outcome, proteinuria and hematuria (Joy MS, 2008; Keane & Eknoyan, 1999). In 
some cases these initial presentations are temporary and can be resolved through early drug 
interventions. However, in most of the cases there is a decrease in the creatinine clearance and 
accumulation of waste products like urea and uric acid (Joy MS, 2008).  
 
The overall functioning of the kidney can be estimated based on two parameters, namely 
glomerular filtration rate (GFR) and creatinine clearance (CC) (KDOQI., 2002; Smith, 1951). 
GFR is defined as the amount of the blood that is filtered by Bowman’s capsule per unit of time 
(mL/min/1.73m
2
). A healthy human should  have a GFR of 120-130 mL/min/1.73m
2 
(Smith, 
1951). However, GFR is dependent on several factors like age, sex, and body size. Additionally,  
GFR estimation through inulin and radioactive isotopes is quite expensive and time consuming 
(KDOQI., 2002). Therefore, CC is an immediate and economical method that is more frequently 
used in clinical practice for GFR based on creatinine (KDOQI., 2002). Two common equations 
are used in practice for the estimation of GFR based on serum creatinine (Scrt). These are  the 
Cockcroft-Gault equation (Cockcroft, 1976) and the Modification of Diet in Renal Disease 
(MDRD) equation (Levey et al., 1999), both of which are defined below:  
2 
 
Cockcroft-Gault Equation 
CC (ml/min)= ([140-Age X weight] / [ 72 X Scrt ]) X 0.85 if female  
 
MDRD Equation 
eGFR (ml/min/1.73 m
2 
) = 186 X [Scrt] – 1.154 X [Age] – 0.203 X [0.742 if female]  
Note: for African/ Black use the multiplication factor 1.21  
  
Based on the CC or eGFR, kidney disease is classified in the following five stages (Hudson, 
2008; KDOQI., 2002):  
i. Stage One: normal or increased GFR (90 or more mL/minute/1.73m2) 
ii. Stage Two: mild decrease in GFR (60–89 mL/minute/1.73m2) 
iii. Stage Three: moderate decrease in GFR (30–59 mL/minute/1.73m2) 
iv. Stage Four: severe decrease in GFR (15–29 mL/minute/1.73m2) 
v. Stage Five: kidney failure (less than 15 mL/minute/1.73m2) or on dialysis 
 
Creatinine is the bi-product of protein metabolism. When the kidney function starts to 
deteriorate, clearance from kidney is reduced, which leads to an elevation in Scrt, urea, and uric 
acid (UA) (Cockcroft, 1976). Most of the patients in stage 4 and stage 5 get frequent dialysis 
based on their renal reservoir. In general most of the patients get dialysis three times a week.  
The main purpose of dialysis is to act as an artificial kidney for elimination of waste products 
from the blood; mainly urea, nitrogen, UA, and excessive electrolytes. In routine practice, two 
types of dialysis are used.  
 Hemodialysis (HD) 
 Peritoneal dialysis (PD) 
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In HD the whole blood is filtered with the help of filters and various dialysis solutions. 
Before initiating the dialysis, a vascular access is created through which the blood is drawn into 
the dialysis machine, where it passes through a membrane or a filter. Along with this a dialysis 
solution is pumped by the machine on the other side of the semi permeable membrane. In this 
way, the waste products that are higher in concentration in the blood are drawn to the dialysis 
solution based on the concentration gradient. Once this exchange happens the dialysis solution 
containing waste products is pumped out of the machine in the waste bin and blood is pumped 
back into the body. This whole process may take 2-5 hours based on the condition of the patient 
(National Kidney and Urologic Diseases Information Clearinghouse NKUDIC, 2006). However 
in peritoneal dialysis (PD) instead of making a vascular access, a catheter is placed in the 
peritoneal cavity (PC). The same dialysis solution is used to fill the cavity and is removed on a 
periodic basis to eliminate the waste products that are exchanged via the PC into the dialysis 
solution. At the moment this method is widely applied in developed countries but rarely seen in 
developing nations (Wiggins, Johnson, Craig, & Strippoli, 2007). 
1.1 Incidence of end stage disease in Saudi Arabia 
 
 
According to the recent statistics published by the Saudi Center for Organ 
Transplantation (SCOT., 2012), there were 13,356 dialysis patients. Of these, 12,116 were on 
HD and 1,240 were availing PD. The overall prevalence estimate for end stage renal disease 
(ESRD) was 492 cases/ per million populations (pmp). In terms of the facilities, there were 182 
dialysis centers equipped with a total of 4,755 dialysis machines that met the HD needs of the 
patients across the kingdom.  Demographic facts revealed that the majority of patients suffering 
from ESRD were in the 26-75 years age group. Additionally, 6.4 % were more than 75 years of 
age, while 1.3 % was less than 15 years of age. While assessing the comorbid complications, it 
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was observed that 61.0% of ESRD patients are hypertensive and about 45.0% suffer from 
diabetes mellitus. In terms of gender, about 44.0% of patients are female and 56.0% are male. 
Unlike many developed nations, Saudi population enjoys free access to all sorts of minor and 
major medical treatment.  For renal failure patients in particular, there are about a 127 dialysis 
centers that are functioning across Saudi Arabia and about 4264 HD machines available.(SCOT., 
2012)  
Looking at the scenario regionally, there are about 1505 patients registered for HD in the 
eastern region of Saudi Arabia with 262 government outlets that are equipped with 324 
machines. Of these, about one hundred dialysis machines are available at the Al-Jaber Kidney 
center, Eastern province, Alahsa (SCOT., 2012), that are providing services to 314 ESRD 
patients. 
1.2 Dermatological problems associated with ESRD 
The dermatological complications are one of the main challenges faced by the majority of 
patients with ESRD. However in most cases these complications are not only due to the ESRD, 
but more associated with comorbid medical complications from which the patient is suffering 
from or due to the biochemical and physiological changes that may appear due to dialysis. 
Patients with comorbid diabetes mellitus on top of ESRD are at higher risk of facing 
dermatological complications like eruptive xanthomas, and diabetic dermopathy (P. Maurice & 
Neild, 1997; P. D. Maurice, 1997). These dermatological changes further trigger  dermatological 
complications like uremia pruritus (UP) (Farrell, 1997). About 85.0% of  mucocutaneous 
abnormalities occur in autoimmune conditions like systemic lupus erythematous (SLE) (Tebbe et 
al., 1997). 
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 Based on lab parameters, uremia is one of the most important parameters resulting in 
many complications that can be internal/organ-related or can be related to the skin.  Among all, 
UP is a frequently found complication reported by the majority with ESRD. Overall, UP affects 
50-90% of patient with ESRD (Patel, Freedman, & Yosipovitch, 2007). Those receiving dialysis 
soon after being diagnosed with ESRD often report relief from UP. However within six months, 
the itching symptoms may reappear with a higher degree of severity, regardless of any 
demographic variables. In general almost all body parts are affected, however the forearms and 
back are more likely to get affected compared to other parts. To date, it is a bit difficult to 
associate uremia with UP. Therefore, UP is also known to be associated with some other 
metabolic changes that may together trigger or potentiate UP i.e. xerosis, decreased 
transepidermal elimination of pruritogenic factors, hyperparathyroidism (which cause 
hypercalcemia and hyperphosphatemia), elevated levels of histamine and transdermal mast cell 
proliferation, and uremic sensory neuropathy. Along with these internal factors some  external 
factors are also assumed to be associated with UP i.e excessive sweating, hot weather, 
dehydration, stress, and shower with cold/hot water (Patel et al., 2007).  
1.3 Epidemiology of UP  
Earlier data from the 70’s showed a very high incidence of UP among ESRD patients. In 
some  studies the incidence is reported among 90.0% of the population (A. W. Young, Jr. et al., 
1973). However, it seems to reduce to 60-70% by the mid-80, perhaps due to a better 
understanding toward the pathogenesis of the disease (P. L. Bencini et al., 1985; Hiroshige & 
Kuroiwa, 1996; Mettang et al., 1990). Recent studies report variable incidences of UP among 
their study population, from 40-70% (Jamal & Subramanian, 2000; Vandana S Mathur et al., 
2010; Mistik et al., 2006; I. Zucker, G. Yosipovitch, M. David, U. Gafter, & G. Boner, 2003). 
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Thus skin integrity is found to be at risk among the ESRD population receiving dialysis or renal 
replacement therapy. Along with these anatomical consequences, UP has a major impact on the 
sleep quality, psychosocial and social wellbeing of patients (Dalgard, Lien, & Dalen, 2007; 
Klang, Björvell, Berglund, Sundstedt, & Clyne, 1998; Szepietowski, Balaskas, Taube, Taberly, 
& Dupuy, 2011b).  With continuous research in basic health sciences, UP prevalence has 
declined compared to the past. However, due to complex processes involved in the generation of 
UP stimuli, UP remains a major clinical symptom and in severe cases often a medical challenge. 
1.4 Pathophysiology of UP  
 
The pathophysiology of UP has always been associated with multiple factors like; 
biochemical changes in patients’ blood (uremia and Calcium/Phosphate imbalance), changes in 
skin physiology, and external factors like temperature, humidity etc. However, without 
understanding the neuropathic pathways it is hard to understand the whole mechanism. Based on 
the nature of predisposing factors, UP can be localized or systemic which may originate from 
peripheral or central stimuli. Along with other predisposing factors, it will not be wrong to 
assume that the UP can be triggered or potentiated due to the stimuli’s that originated in response 
to the chemical mediators which in turns excite the neurons to initiate itching/UP. Based on the 
stimuli’s and predisposing factors, UP can be classified into;  
 Neurogenic Pruritus that occurs mainly due to neurophysiological dysfunction, 
cholestasis or psychotropic medication 
 Neuropathic Pruritus that occurs mainly due to a primary neurological disorder  
 Pruritogenic pruritus  that arises from  skin diseases 
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Most of the mechanisms, however,  are postulated (P. Maurice & Neild, 1997). Despite 
this, they have contributed greatly in the understanding of how to manage the severity of UP 
using a blend of neuropathic and other pharmacotherapeutic agents. Based on these postulations, 
extensive research have been done to address the possible mechanisms of UP among patients 
with ESRD. Clinical trials have shown that the pathophysiology of UP among ESRD patients 
can be due to two main hypothesis, namely immune and neuropathic.  
          The immunohypothesis suggests that UP among ESRD is triggered by systematic 
inflammatory pathways rather than a skin disorder. Trials testing the effectiveness of ultraviolet 
B radiations (UVBR) strongly support this hypothesis (Keithi-Reddy, Patel, Armstrong, & 
Singh, 2007; Patel et al., 2007), and it has been shown that UVBR decreases the production of 
TH1-type lymphocytes (TH1L). T- Lymphocytes (TLs) have a vital role in the immune system 
of the human body. Upon proliferation, TLs are differentiated into effector T cells i.e. TH1L and 
TH2L. These effector T cells are responsible for immunity/ memory and the production of 
antibodies. In the case of UP among ESRD patients, TH1Ls favor the production of TH2Ls 
which in turn increases the production of inflammatory biomarkers like interleukins (ILs). In 
addition, it is evident that the number of CXC chemokine receptor 3 (CXCR3)- expression and 
interferon secreting CD4+ cells are higher among patients with ESRD (Kimmel M et al., 2006). 
These inflammatory biomarkers have a very vital role in the TLs differentiation. In addition, the 
levels of other inflammatory bio-markers like reactive proteins (C), and Interleukin-6 (IL-6) are 
found to be higher among patients complaining of UP (Saifullah et al., 2007). Based on the trials 
using UVBRs to treat UP among ESRD patients, some researchers are convinced with the 
immuno-hypothesis (Keithi-Reddy et al., 2007; Patel et al., 2007; Qureshi et al., 2002).  
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The second hypothesis advocates the involvement of central and peripheral systems, thus 
emphasizing more on the neurogenic nature of the disease. Another hypothesis advocates the 
involvement of the peripheral and central nervous systems to trigger pruritus (Langner & 
Maibach, 2009; Gil Yosipovitch & Lena S. Samuel, 2008). It was assumed that the stimulus for 
pain and UP is generated through the same pathways. However, recently it was confirmed that 
the neural pathway triggering UP is unique and distinct from the pain pathway (Ikoma, Steinhoff, 
Ständer, Yosipovitch, & Schmelz, 2006). The activation of the neuronal cells occur in response 
to the chemical mediators (Amines, proteases, neuropeptides, opioids, eicosanoids, growth 
factors, and cytokines) that stimulate neurons to cause an itch (Weisshaar, Kucenic, & Fleischer, 
2003). In the light of these two hypotheses, therapeutic management of UP is mainly comprised 
of emollients, local / oral anti-inflammatory drugs and neuroleptic drugs, anti-psychotics, and 
anti-depressants.  
1.5  Challenges in the assessment and management of UP among ESRD patients  
The assessment of pruritus is perhaps one of the most challenging aspects in the 
management of UP among ESRD patients. Most of the studies have used the visual analogue 
scale (VAS) [ranging from 0-10] to measure the intensity of the pruritus (Aucella & Gesuete, 
2009a; Feily et al., 2012; Hampers, Katz, Wilson, & Merrill, 1968; Kim, Lee, Choi, & Ernst, 
2010). However, the VAS assessment suffers serious criticism due to its narrow spectrum to 
cover the diverse intensity of an itch (Elman, et al., 2010). The assessment may be biased and 
unable to measure the exact intensity of an itch particularly among elderly and young patients, 
especially those with cognitive and motor complications (Peters, Patijn, & Lame, 2007). 
Moreover, the use of the VAS for the assessment limits the investigators’ capability to assess the 
multidimensional assessment of UP. Thus a comprehensive assessment of UP cannot be 
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measured using a simple VAS (Elman et al., 2010). While addressing the management of UP, 
three main challenges are there; first of all is the systemic nature of UP that is believed to be an 
outcome of a variety of factors. As such the use of an emollient alone is ineffective, and systemic 
agents are preferred over tropical therapies, or tropical agents can be used in combination with 
the systemic treatment option. Second is the variation in the pharmacokinetics among ESRD 
patients i.e.  The compromised renal clearance of drugs and low serum plasma albumin increases 
the chances of toxicity and side effects of the oral therapies selected to treat UP. The third one is 
treatment-resistance pruritus, which is resistant or non-responsive to most of the tropical and 
systemic agent that are used alone or in combination.  
Moreover, in ESRD patients dialysis are done mostly three times a week, due to which it 
is really impossible to associate the severity of UP with one of the lab parameters (Xander et al., 
2013). In recent years the use of neuroleptic agents like gabapentin and PG has increased 
massively for the management of treatment resistant UP. Neuroleptic agents like gabapentin 
have been found to have good effectiveness in treating pruritus that is resistant or non-responsive 
to tropical and other systemic treatment options (Xander et al., 2013). However, in some 
situations when patients are unable to tolerate gabapentin,  pregabalin  (PG)  has been  found  to 
be  effective  in  providing  relief in  the  patient’s condition (Rayner et al.,  2013; Solak et al.,  
2012). Gabapentin and PG have drastic differences in their pharmacokinetics and 
pharmacodynamics. Gabapentin oral absorption is slower than PG, which attains its plasma peak 
concentration within 1 hour. Furthermore, the dose-dependent concentration increase is not one 
of the characteristic of gabapentin. However, surprisingly the bioavailability of gabapentin 
reduces from sixty to 33.0% when the dose increases from 900 mg/day to 3600 mg/day 
(Randinitis et al., 2003). Meanwhile for PG, the bioavailability remains more that 90.0% 
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regardless of dose increase. These pharmacokinetic benefits provide a pharmacodynamics edge 
to PG over gabapentin. Thus the therapeutic effectiveness of PG for labeled and non-labeled 
indications is better than gabapentin (Randinitis  et al., 2003).  
However among ESRD patients, gabapentin is often not tolerated due to compromised 
renal function, poor oral absorption and low bioavailability of gabapentin is another challenge. 
Therefore for ESRD patients, higher doses of gabapentin are required which increases the risk of 
adverse events associated with its use (Solak et al., 2012). However, PG is superior to 
gabapentin in this regard. Recent preliminary studies conducted among UP patients have shown 
benefits for PG use over gabapentin. Moreover, the recommended dose of gabapentin for ESRD 
patients is 100-300 mg per day, while for PG the recommended dose ranges from 25-75mg per 
day (Rayner et al., 2013). In other words, PG can give a better response at a lower dose in 
comparison to gabapentin (Rayner et al., 2013).  
1.6   Research Question  
The literature review provides a very diverse picture of the methods that are used to 
investigate the different treatment options to test their therapeutic potential to treat UP. Without 
any conflict, randomized clinical trials (RCT) are the gold standards to investigate and provide 
solid evidence about the effectiveness of the intervention and their outcomes. However, when 
RCT requires a great deal of cost and resources or due to some local/ regulatory legislation issues 
RCT may not be possible. Then longitudinal studies with repetitive assessment can provide an 
ideal way to measure the effect of intervention over time. While addressing the issues concerning 
the quantification of UP, VAS is used by the majority of researchers. However, some of the 
recent studies promote the use of new tools i.e. 5D-IS that can compute the multidimensional 
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nature of the disease, and also can assess the impact of pruritus on quality of life. Furthermore, in 
repetitive assessments using 5D-IS, the sensitivity of 5D-IS was more accurate in comparison to 
other tools. Thus results generated using 5D-IS can be more effective or accurate to compute the 
intensity of UP among patients with ESRD. In addition, from the literature it is also seen that 
most of the studies have given priority to assess the treatment effectiveness only. The adverse 
events associated with the use of these medicines are not provided by the majority. Those 
documenting such events have only shared subjective assessment and have not assessed the 
significance of such events on scientific grounds. In the light of the cited evidence the current 
study plan is to assess the effect of PG using a longitudinal study with repetitive measure using 
5D- IS as a tool to quantity the severity/ intensity of UP. While focusing on the PG safety 
aspects, and keeping PG manufacture monograph as a standard, a criteria will be devised for the 
selection of patients; those facing any side effects will be assessed properly using the Naranjo’s 
algorithm, so that the probability of PG to cause an event can be justified on scientific grounds. 
Further details about the study design, selection criteria and Naranjo’s algorithm are discussed in 
detail in the methodology section.  
1.6.1 Problem statement  
Treatment resistant UP remained to be one of the most challenging complications for the 
ESRD patients. A recent longitudinal study conducted by Shavit  et al., (2013) has reported on 
the  therapeutic effectiveness of  PG  25-50mg/ day among uremic patient with treatment 
resistant pruritus showing resistance to antihistamines and emollients (Shavit  et al.,2013). In 
addition  Aperis et al., (2010);  and  Rayner et al.,  (2013)  have also reported  on the  
effectiveness of  PG  25mg/day among ESRD  patients with treatment resistance pruritus 
(previously tested for emollients, antihistaminic and UV light). Overall, patients were found to 
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be satisfied with the effect of PG on the severity of pruritus. Considering the results of the three 
studies, the profound effect of PG is noticeable. However, critical analysis of the results shown 
by Shavit  et al.,  (2013); Aperis  et al.,  (2010);  and Rayner  et al.,  (2013) reflects the need of 
methodologically strong studies. Moreover, most advocated the daily use of 25-50mg/day to 
manage UP. However, administering a single dose 75mg/day post HD is not yet investigated.  
PG is cleared through renal excretion, thus if the PG single dose 75mg/day post HD (pHD) is 
found effective. In addition it is also a cost effective option because of the cost of 75mg single 
dose pHD is 15.86 Saudi riyal (SR) and in comparison to 25mg or 50mg once daily (25mg 
1caps. = 8.75 SR x 3day= 26.25 SR for 3 days; 50 mg 1caps. = 11.25 SR x 3day= 33.75 SR for 3 
days). Thus using single dose 75mg PG pHD will give a cost-effective option to manage UP 
among ESRD patients. Moreover, in the case if patients are receiving PG 25mg & 50mg (once or 
twice daily), the like hood of adverse event will become double due to repetitive exposure.  
However, in the case if a 75mg single dose PG is used after each dialysis the chances of adverse 
effects can be reduced due to decease in the frequency of administration. 
Addressing the safety profile of the  PG  the drug development data  only  reflects  the  
PG safety among health population and till to date  there is limited safety data for  PG  among 
ESRD patients  (Pregabalin, 2009).  Recent case studies and case series have reported some 
adverse events that were found associated with the use of  PG  among patients with treatment 
resistant pruritus  (Aperis, et al.,  2010;  Ehrchen & Stander, 2008;  Rayner et al.,   2012;  Shavit 
et al.,  2013;  Y. Solak et al.,  2012). However, the significance and probability of these events is 
not yet tested. To conclude a potential association of these events with the PG use there is need 
of systematic assessment that confirms the significance of any undesired event with the PG use. 
Naranjo’s algorithm is considered as one of the valid, sensitive and specific tool that have 
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assisted the clinicians to predict the probability of any undesired event with the use of any drug 
(Kathleen & Terry, 2003; Naranjo  et al.,  1981).  However, it is never used to estimate the 
probability of the events associated with the use of PG.  Furthermore in global and Saudi clinical 
setting Naranjo’s algorithm assessment are widely used to predict the probability of the drug 
related events (Khan, Al-Harthi, & Saadah, 2013; Smyth et al., 2012). Keeping in view the 
discussion above, two main issues need to be addressed; one is the effectiveness of 75mg PG 
pHD among patients with treatment resistant UP and second is the systematic assessment to test 
the probability of adverse event among ESRD patient taking PG therapy.  With this as a 
motivation, the current study aims to investigate the therapeutic effectiveness and safety of 75mg 
PG pHD among ESRD patients with treatment-resistant UP. 
 
1.7 Aims of study  
 To assess the therapeutic effectiveness of 75 mg PG pHD in treatment-resistant UP 
among ESRD patients. 
1.7.1   Specific objectives of Study  
 Linguistic validation of 5D itching scale  (5D-IS) and its reliability to assess UP among 
patients with ESRD 
 To investigate the effectiveness of 75mg pHD dose of PG among patients with treatment-
resistance UP 
 To assess the safety and tolerability of PG among ESRD patients using the Naranjo’s 
algorithm. 
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1.8 Working definitions  
 
 Source language: The source original language of the study tool (Wild et al. 2005). 
 Target language: The language in which the questionnaire or study tool will be 
translated (Wild et al. 2005).  
 Instrument developer: The instrument developer is the person, people or groups 
who have developed the questionnaire or study tool (Wild et al. 2005). 
 Project manager: “project manager” refers to the person who liaises with all the 
defined groups that are participating at the different stages of language translation 
(Diane W et al., 2005; Hasson F., Keeney S., & McKenna H., 2000; McKenna HP, 
1994).  
 Forward translator: A forward translator is an individual who has performed the 
second forward translation of the questionnaire or study tool into the target 
language (Wild et al. 2005). 
 Proofreaders: These individuals reviewed the translated tool to identify any 
grammatical mistakes or typing errors (Wild et al. 2005). 
 Treatment resistant UP: UP that is resistant to the one month therapy of 
conventional therapeutic options i.e emollients, anti-histaminic alone or in 
combination with emollients.  
 Probability of adverse events: is estimation based on the score calculated from 
Naranjo’s algorithm.  (Jones, 1982; Kramer & Hutchinson, 1984; Naranjo et al., 
1981). 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.0 Etiology of UP and its prognosis  
 
Pruritus or itch  is the outcome of an unpleasant sensation which triggers stimuli resulting 
in an urge or desire to scratch (G. Yosipovitch, M. W. Greaves, & M. Schmelz, 2003). The 
International Forum for the Study of Itch (IFSI) classified pruritus into six categories based on 
the nature of the pruritus – systemic, dermatologic, neurologic, psychogenic, mixed and other 
(Matterne et al., 2011; Stander et al., 2007).  The classification of pruritus is not exclusive as it is 
often multifactorial (Stander et al., 2007). In contrast to acute pruritus, pruritus that lasts for 6 
weeks or more is classified as chronic pruritus by the IFSI (Matterne et al., 2011; Stander et al., 
2007). Patients with ESRD often suffer from chronic intense itch which is known as uremic 
pruritus (Dar & Akhter, 2006). Incidence of uremic pruritus (UP) is reported in 50-90% of 
hemodialysis patients (HDPs) (Matterne et al., 2011; I. Narita, S. Iguchi, K. Omori, & F. Gejyo, 
2008).  
Unresolved or poorly managed uremic pruritus often leads to reduced quality of life, 
depression, impaired quality of sleep and increased mortality rate (Dar & Akhter, 2006; V. S. 
Mathur et al., 2010; Pisoni et al., 2006; G. Yosipovitch et al., 2003). The dialysis adequacy of 
these patients is often assessed by Kt/V value where an optimal threshold of ≥ 1.5 and the use of 
a high-flux dialyzer to improve the condition of pruritus and other associated uremic symptoms 
such as fatigue, anorexia, nausea and insomnia (Ko et al., 2013; Liakopoulos et al., 2004). 
However, objective assessment of the severity of the UP is required as the intensity of itch can be 
subjective and varies among patients. This can be achieved with a comprehensive and reliable 
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questionnaire (Mathur et al., 2010; G. Yosipovitch et al., 2001; Zucker, Yosipovitch, & Boner, 
1999), a  numerical rating scale or more commonly with the visual analogue score (VAS) – often 
a 10 point pruritus score with 0 being no pruritus and 10 being the worst imaginable pruritus (A. 
Reich et al., 2012).  
Addressing the prognosis of UP various factors has been postulated that contribute to UP. 
Some postulate the accumulation of pruritogens by using less permeable membranes such as a 
cuprophane dialysis membrane (Twycross et al., 2003) While some advocate the  involvement of  
systemic factor and  xerosis as one of the potential factors that aggravate pruritus (Falodun, 
Ogunbiyi, Salako, & George, 2011; Kfoury & Jurdi, 2012; Szepietowski, Reich, & Szepietowski, 
2005; Urbonas, Schwartz, & Szepietowski, 2001; Welter Ede, Frainer, Maldotti, Losekann, & 
Weber, 2011). Where Xerosis is the causative agent, frequent application of emollients is found 
to be beneficial (Anand, 2013;Greaves, 2005). Furthermore, some metabolic changes i.e. 
secondary hyperparathyroidism is assumed to play a vital role in the prognosis of UP by 
increasing the  mast cell secretion (Tsakalos, Theoharides, Kops, & Askenase, 1983). Secondary 
hyperparathyroidism causes elevation of divalent ions such as magnesium, phosphate and 
calcium; this may result in a  micro-precipitation that is known to have a role in  modulation of 
mast cells degranulation (Manenti, Tansinda, & Vaglio, 2009). Improvement is noticed with 
parathyroidectomy (Chou, Ho, Huang, & Sheen-Chen, 2000; Hampers, Katz, Wilson, & Merrill, 
1968). A high serum phosphorus level was recently found to be significantly lower in HDPs with 
more severe and frequent pruritus compared to those without pruritus (Gatmiri, Mahdavi-
Mazdeh, Lessan-Pezeshki, & Abbasi, 2013). Other factors that are associated with UP include 
production of pruritogenic substances such as cytokines, abnormal growth and sprouting of “itch 
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fibers” in the skin, and neuropathy that leads to the increase in the threshold for itch (L. Manenti, 
Vaglio, & Borgatti, 2008; Metz & Stander, 2010).  
 Due to the involvement of multiple factors, several pathogenesis mechanisms have been 
hypothesized, and they form the foundations of therapeutic management of UP (Aucella & 
Gesuete, 2009). Currently, three hypotheses are being postulated to address the pathogenesis and 
prognosis of uremia pruritus. The immune hypothesis refers to uremic pruritus as an 
inflammatory disease due to the overproduction of pro-inflammatory substances such as 
histamine (by mast cells), interleukin 2, TNF -α and interferon γ by T Helper 1 lymphocytes 
(Balaskas & Grapsa, 1995; Namazi, Fallahzadeh, & Roozbeh, 2009). The inflammatory nature of 
uremic pruritus is supported by the elevated level of inflammatory markers such as interleukin 6 
and C-reactive protein (H. Y. Chen et al., 2010; Fallahzadeh, Roozbeh, Geramizadeh, & Namazi, 
2011; M. Kimmel et al., 2006); while a neuropathic hypothesis suggests the somatic and 
autonomic neuropathy caused by lesion can result in neuropathic itch (Twycross et al., 2003; G. 
Yosipovitch & L. S. Samuel, 2008). It has been established that neuropathic pain and pruritus 
share the same neuronal pathway (Kfoury & Jurdi, 2012). Moreover, it is also suggested that 
afferent C-terminal nerve fibers that are gaba-aminobutyric acid (GABA) dependent are also 
involved in the augmentation of UP (Rayner, Baharani, Smith, Suresh, & Dasgupta, 2012). 
However, the opioid hypothesis suggests that imbalance in the endogenous opioidergic system 
plays an important role in the pathophysiological mechanism of UP through μ receptor 
antagonists and ϰ receptor agonists to relieve itch (Kfoury & Jurdi, 2012; Nakao & Mochizuki, 
2009; A. Reich et al., 2012). Activation of the μ -opioid receptor is shown to be centrally 
involved in the mediation of pruritus while activation of the ϰ-opioid receptor has an inhibitory 
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effect on the μ-opioid receptor both peripherally and centrally (Kfoury & Jurdi, 2012; Kumagai 
et al., 2010; Nakao & Mochizuki, 2009; A. Reich, Stander, & Szepietowski, 2011). 
2.1 Objectives of Literature review  
 
Despite being commonly experienced by hemodialysis patients (HDPs).  The 
management of UP remained as one of the main clinical challenge to the treatments of UP. In 
this review,  all hypotheses are being put forward to explain the pathophysiology of uremic 
pruritus using various trials and studies that examined the effectiveness of different agents in the 
management of UP in HDPs. The literature review chapter mainly focuses on exploring three 
main issues  
 Treatment options in the evidence-based literature  for the management of UP 
 Different methodological design and their effectiveness  
 Assessment method for Itching/Pruritus   
2.2 Literature search 
 
All the human studies (published in English) investigating different treatment options for 
the management of pruritus patients were searched for from databases that included PubMed, 
EMBASE, Cochrane CENTRAL, from January 2000. The medical subject headings (MeSH) and 
keywords used for the search were “pruritus and end stage renal disease, or uremic/ uremia 
pruritus among /and end stage renal disease, or pruritus uremic/ uremia pruritus among/and 
dialysis patients, or itching among /and end stage renal disease, or itching among/and dialysis 
patients or itching/ itch among uremic patients”. Studies that were a randomized controlled trial, 
prospective uncontrolled study, retrospective cohort study, case-control study, case series or case 
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reports were included for the systematic assessment. During data extraction, duplicate articles 
were removed and the clinical heterogeneity and assessment was performed according to the 
PICO (Patient, Intervention, Comparator and Outcome) principle. 
2.2.1 Findings from literature 
 
2.2.1.1 Treatment options in the evidence-based literature for the management of UP 
 
 The main purpose of this section of literature was to extract data from the relevant 
literature. The following inclusion criteria were used for potential inclusion in the literature 
review.  
 The research has to focus on management of UP 
 Study population should be comprised of ESRD patients on dialysis  
 Research recommending or involving the invasive procedure as a measure to ensure the 
outcome i.e. biopsy, fine needle aspiration were excluded.  
 Relevant literature till 31st April 2014 was included in the study 
After applying the inclusion criteria, 32 articles were eligible and they are included in this review 
and summarized.  
 A study conducted by Shavit et al., (2013) examined the potential use of PG in the 
treatment of UP in patients with ESRD. A total of 12 CKD patients who suffered from 
uremic pruritus were enrolled and had the intensity of their pruritus assessed using VAS 
(0 = no itch to 10 = severest itch) before starting the PG treatment. Initial dose of 25mg 
PG was orally administered 3 times weekly after each HD session and increased to 25mg 
per day if no improvement in pruritus was observed and subsequently to 50mg per day. 
The primary end point in this study was reduction in baseline VAS for 50% or more 
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within the first two weeks of PG treatment. The baseline mean VAS was 9.7 and it 
decreased significantly to 3.7, 3.2, and 3 after the first, fourth, and 24
th
 weeks of the 
treatment correspondingly (p <0.05). Six patients experienced positive improvement in 
the first week of treatment; one patient improved with increased dose at 25mg per day 
and three patients required 50mg per day. PG was generally well tolerated despite two 
patients experiencing dizziness and somnolence. 
 
 In an open-label cohort study that lasted for a median of 2 months, Rayner et al., (2012) 
examined the use of gabapentin and PG in 71 patients with CKD Stage IV and V. 
Severity of itch was assessed before treatment using a visual analogue scale (VAS. 
Starting dose of gabapentin was given at 100mg daily after the HD session.  Doses were 
adjusted based on their symptoms by their physicians. Mean itch severity decreased from 
8 (range = 6 to 10) to 1 (range = 0 to 6) after average gabapentin treatment of 2 months in 
47 patients (66%). Twenty-six patients (37%) experienced side effects such as dizziness 
and over-sedation from gabapentin and 16 out of 21 patients who stopped gabapentin 
treatment due to side effects were treated with PG at 25mg once daily after each HD 
session. Thirteen patients (81%) achieved mean itch severity of 2 (range = 0 to 5) after 
average PG treatment of 2.5 months. Three patients stopped PG treatment – 1 due to no 
improvement in the pruritus and 2 due to over-sedation.  They concluded that PG can be 
given when gabapentin is not tolerated by the patients. Thus reflecting the equal efficacy 
for PG in comparison to gabapentin and ESRD patients with UP. 
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 A study by Aperis et al., (2010) examined the effect of PG in the treatment of uremic 
pruritus in 16 white Caucasian ESRD patients. Any treatments for UP was stopped one 
week before the PG treatment and severity of itch was assessed with VAS with scores 
from 0 (no itch) to 10 (worst imaginable pruritus). Patients were started on 25mg PG 
once daily in the evening before bedtime for 1 month. There was a significant reduction 
in itch severity from the baseline 7.44 ± 2.01 to 1.7 ± 1.31 (p<0.0003) after the PG 
treatment. However, 4 patients discontinued the treatment due to side effects – 3 suffered 
from somnolence and dizziness and 1 suffered from hand tremor and blurred vision. 
 
 In a placebo-controlled clinical trial, Naini et al., (2007) examined the effect of 
gabapentin in the treatment of uremic pruritus compared to placebo. Thirty four patients 
on HD were enrolled and randomly allocated to receive either 400mg gabapentin or 
placebo twice weekly after each HD session for 4 weeks. Treatments used for their anti-
pruritic effects were discontinued 1 week before the initiation of the gabapentin 
treatment. Pruritus severity was objectively assessed with VSA ranging from 0 (no itch) 
to 10 (worst possible itch). After 4 weeks of gabapentin treatment, the mean pruritus 
score reduced from the baseline 7.2 ± 2.3 (range = 3-10) to 6.7 ± 2.6 and 1.5 ± 1.8 in 
patients treated with gabapentin and placebo respectively (p<0.001). Although no patients 
left the study, dizziness, nausea and somnolence were the most common side effects 
experienced by the patients and these symptoms subsided 5-10 days after the first dose of 
gabapentin.   
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 A double-blind placebo control clinical trial by Razeghi et al., (2009) examined the effect 
of gabapentin at 100mg thrice a week pHD. Patients were given 100mg gabapentin orally 
three times a week for 4 weeks and then after 1 week of a wash out period, placebo was 
given for another 4 weeks. A total of 9 patients dropped out due to side effects such as 
drowsiness, dizziness and fatigue, one showed no sign of improvement after 10 days of 
treatment, and 6 were excluded due to poor compliance. The pruritus score reduced from 
the baseline line 100 to mean 6.44 ± 8.46 (p<0.001) at the end of the gabapentin 
treatment and increased to 15 ± 11.27 (p<0.001) during the wash out period— and 
increased further to 81.88 ± 11.06 (p<0.001) after giving placebo. Other parameters such 
as mean albumin serum (p=0.84), mean C-reactive protein (p = 0.42) were found to have 
no correlation with the mean pruritus score throughout the treatment. The study 
concluded that at a lower dose of 100mg, gabapentin offered similar benefit as when it 
was administered at 300mg and associated with fewer side effects. 
 
 A 14 week-long prospective and cross-over trial of PG versus (VS) gabapentin was 
conducted among uremic patients with neuropathic pain. Solak et al., (2012) reported that 
both treatments improved the condition of pruritus as well as neuropathic pain in patients 
on HD. Patients underwent a 6 week wash out period before initiation of the treatments. 
Fifty patients were allocated with a number randomly generated by computer to receive 
either gabapentin 300mg 3 times a week after each HD session or PG 75mg daily for 6 
weeks. Both treatments were administered at the maximum recommended dose by the 
manufacturers and the severity of pruritus and neuropathic pain was assessed VAS and 
the Short-Form McGill Pain Questionnaire (SF-MPQ). A 2 week wash out period was 
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conducted before cross-over was performed and the reversed treatment was continued for 
another 6 weeks. Both gabapentin and PG reduced the mean pruritus score significantly 
from the baselines of 5.87 ± 1.38 and 5.8 ± 1.4 to 1.43 ± 2.0 (p<0.001) and 1.36 ± 2.32 
(p<0.001) respectively, after 6 weeks of treatment. The difference in terms of efficacy 
between gabapentin and PG was found to be insignificant in the treatment of neuropathic 
pain (difference from baseline after 6 weeks of treatment: 8.9 ± 4.1 for gabapentin and 
9.3 ± 4.0 for PG, p=0.576) and in the treatment of UP (difference from baseline after 6 
weeks of treatment:  4.41 ± 1.78 for gabapentin and 4.43 ± 2.1 for PG, P=0.844). Both 
drugs were well tolerated although 10 patients (5 from each treatment group) dropped out 
from the study due to side effects such as dizziness, somnolence, dry mouth, diarrhea and 
tremor. 
 
 In a 4 month randomized clinical trial, Shakiba et al., (2012) explored the efficiency of 
sertraline as a potential treatment for UP in 19 ESRD patients on HD. Detailed history of 
pruritus was obtained and the patients were allocated into groups according to the grade 
of their pruritus - 10 patients with severe pruritus and 9 patients with moderate pruritus. 
All patients were treated with 50mg of sertraline orally for 4 months and the symptoms of 
pruritus were re-assessed on a monthly basis. At the end of the treatment, the 
improvement of pruritus in the patients was found to be significant (p=0.001) - 11 
patients (57.8%) were graded with minor pruritus, 6 patients (31.5%) with moderate 
pruritus and only 2 patients (10.7%) with severe pruritus.  
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 A retrospective study by Chan et al., (2013) reported that low-dose sertraline was 
effective in the treatment of antihistamine-refractory UP in ESRD palliative care patients 
not on dialysis. Severity of pruritus was assessed with a Numerical Rating Scale (NRS) 
(0-10) and 25mg sertraline was given orally every day for the first month of the treatment 
and the dose was increased to 25mg monthly based on the clinical response up to a 
maximum of 200mg daily. Medication change and usage of over-the-counter medications 
were not allowed during the treatment period. The primary outcome of the study was 
achieved when patients experienced subjective relief or control of pruritus at the 
minimum dose of sertraline being administered. The NRS score reduced significantly 
(p<0.01) from 7.47±1.605 to 2.47±1.281for the pre- and post-treatment respectively, with 
a mean reduction of 5. The average effective dose of sertraline was 35mg, with a range of 
25mg to 75mg. Sertraline was reported to be well-tolerated with only 3 patients leaving 
after an average treatment of 4.7 days and dizziness and fatigue were observed in these 
patients. 
 
 Marquez et al., (2012) compared the efficacy of gabapentin and desloratidine and their 
side effects in the treatment of UP in an open-label, crossover clinical trial with 22 
eligible patients. Mean VAS score reduced in patients treated with gabapentin - from the 
baseline 5.95(4-8) to 3.4 (P=0.004) and significantly reduced in patients treated with 
desloratidine - from 5.89 to 3.4 (p=0.004). When comparing treatment groups, no 
significant difference was found in the final mean pruritus score (gabapentin 4.6, 
desloratidine 3.4, p=0.16). Fatigue and somnolence were reported in 9 out of 19 patients 
treated with gabapentin after the first dose and 4 patients withdrew from the study due to 
